J-N Chatelet1, M Auffret2, S Combret3, E Bondon-Guitton4, M Lambert5, S Gautier1. 1. Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France. 2. Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France. Electronic address: ma.auffret@gmail.com. 3. Centre régional de pharmacovigilance de Dijon, CHU de Dijon, 21079 Dijon cedex France. 4. Centre régional de pharmacovigilance de Toulouse, CHU de Toulouse, 31000 Toulouse France. 5. Service de médecine Interne, hôpital Claude-Huriez, CHRU de Lille, 59045 Lille cedex France.
Abstract
INTRODUCTION: Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. CASE REPORT: We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus. CONCLUSION: Despite an excellent tolerance and high efficacy-side effect ratio, this case report adds some evidence for an otoxicity of hydroxychloroquine.
INTRODUCTION: Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. CASE REPORT: We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus. CONCLUSION: Despite an excellent tolerance and high efficacy-side effect ratio, this case report adds some evidence for an otoxicity of hydroxychloroquine.